NMN (nicotinamide mononucleotide)
NAD+ precursor with rapidly-growing human RCT base, newer than NR, generally comparable mechanism, regulatory ambiguity in some markets.
Why
Nicotinamide mononucleotide (NMN) is a NAD+ precursor that has become widely available as a supplement, particularly after Sinclair's lab publications and David Sinclair's public advocacy. Multiple human RCTs (Yoshino 2021, Yamane 2022, Pencina 2023) confirm dose-dependent NAD+ elevation at 250–1,000 mg/day. Clinical-outcome RCTs are emerging, modest signals on insulin sensitivity, walking endurance, and sleep, but disease-endpoint trials are not yet available. Regulatory status varies: FDA blocked supplement marketing in 2022 (subsequently uncertain); EU and several Asian markets permit.
How it works
Converted to NAD+ via NMNAT (nicotinamide mononucleotide adenylyltransferase). Whether NMN itself is the active or whether it must be converted to nicotinamide riboside extracellularly before cellular uptake is debated (Slc12a8 transporter vs CD73-mediated pathway).
Expected onset · NAD+ elevation within days-weeks; clinical endpoints assessed over months
How to take
Dosage
250–1,000 mg/day. Most current trials use 250–500 mg/day. Higher doses do not appear to add proportional benefit.
Timing
Once daily, morning; with or without food
On the label
Stated NMN content per dose. Third-party tested for purity (NMN supplements have had widely variable actual content per FDA testing). Refrigeration extends shelf life.
Ideal for
Adults exploring NAD+ supplementation as longevity-focused intervention with awareness that long-term outcome data is absent; older adults with measured NAD+ decline.
Safety
Evidence
Yoshino 2021 Science RCT (n=25 prediabetic postmenopausal women): NMN 250 mg/day raised muscle insulin sensitivity. Pencina 2023 confirmed dose-dependent NAD+ elevation. Preliminary evidence, no Cochrane review, EMA HMPC monograph or EFSA-authorised health claim covers this indication; cited RCTs are small or in non-tier-1 journals. Useful as honest reference rather than evidence-grade recommendation. Regulatory status varies, particularly note FDA's 2022 position blocking supplement marketing in the US.
No Cochrane review, no EMA monograph. Clinical-outcome trials remain small and short-duration. NMN supplement quality varies, FDA testing has found widely variable actual NMN content. Long-term safety beyond 1 year is not yet established.
- Yoshino et al., Science 2021, nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
- Pencina et al., GeroScience 2023, MIB-626, an oral formulation of a microcrystalline unique polymorph of β-nicotinamide mononucleotide, increases NAD+ in humans (RCT)
- Yamane et al., npj Aging 2022, long-term oral administration of NMN safely raised blood NMN/NAD+ in middle-aged and older Japanese adults (RCT)
Where to get it
Shop NMN (nicotinamide mononucleotide) on AmazonSponsored · As an Amazon Associate, Healicus earns from qualifying purchases.